Biocomposites gained a new CE Mark approval for mixing STIMULAN® calcium matrix with the antibiotics vancomycin, gentamicin and tobramycin, for use in infected bone and soft tissue.
STIMULAN targets high concentrations of antibiotic at the point of infection. STIMULAN Rapid Cure and STIMULAN Kit products are the first calcium matrices that can carry an antibiotic into bone and soft tissue. STIMULAN products are used in over 50,000 cases annually.
Michael Harris, Chief Executive Officer of Biocomposites, said, “Our goal is to develop and provide products that can significantly improve patient outcomes and decrease hospital readmissions. This is a breakthrough solution for surgeons managing infection, offering them the flexibility to use their chosen antibiotics at patient-specific concentration levels in both bone and soft tissue.”
Biocomposites gained a new CE Mark approval for mixing STIMULAN® calcium matrix with the antibiotics vancomycin, gentamicin and tobramycin, for use in infected bone and soft tissue.
STIMULAN targets high concentrations of antibiotic at the point of infection. STIMULAN Rapid Cure and STIMULAN Kit products are the first calcium matrices that can...
Biocomposites gained a new CE Mark approval for mixing STIMULAN® calcium matrix with the antibiotics vancomycin, gentamicin and tobramycin, for use in infected bone and soft tissue.
STIMULAN targets high concentrations of antibiotic at the point of infection. STIMULAN Rapid Cure and STIMULAN Kit products are the first calcium matrices that can carry an antibiotic into bone and soft tissue. STIMULAN products are used in over 50,000 cases annually.
Michael Harris, Chief Executive Officer of Biocomposites, said, “Our goal is to develop and provide products that can significantly improve patient outcomes and decrease hospital readmissions. This is a breakthrough solution for surgeons managing infection, offering them the flexibility to use their chosen antibiotics at patient-specific concentration levels in both bone and soft tissue.”
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
